A Phase I Study of SHR-3836 in Patients With Multiple Myeloma

NCT07490613 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

99

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: SHR-3836 administered as multiple doses.

Sponsor

Shanghai Hengrui Pharmaceutical Co., Ltd.